Dietary restriction protects against diethylnitrosamine-induced hepatocellular tumorigenesis by restoring the

Ting Duan1, Wenjie Sun1, Mohan Zhang1

  • 1Department of Toxicology, School of Public Health, Zhejiang University, Hangzhou, Zhejiang, 310058, P. R. China.

Scientific Reports
|March 7, 2017
PubMed

Insights

Dietary restriction (DR) significantly reduces hepatocellular carcinoma (HCC) development in mice by reversing gene expression changes. This approach offers potential new molecular targets for liver cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Nutritional Science

Background:

  • Hepatocellular carcinoma (HCC) is a lethal malignancy with limited effective treatments.
  • Dietary restriction (DR) shows promise in inhibiting tumors, but its mechanisms remain unclear.

Purpose of the Study:

  • To investigate the protective mechanisms of dietary restriction (DR) against diethylnitrosamine (DEN)-induced hepatocellular carcinoma (HCC) in a mouse model.
  • To elucidate the molecular pathways modulated by DR in HCC development.

Main Methods:

  • Utilized a diethylnitrosamine (DEN)-induced HCC mouse model.
  • Performed transcriptome sequencing on liver tissues from DEN-exposed and DR-treated mice.
  • Conducted transcription factor enrichment analysis.

Main Results:

  • DR significantly reduced tumor number, size, and delayed development in the HCC mouse model.
  • DR suppressed cancer cell proliferation and promoted apoptosis.
  • Transcriptome analysis revealed DR reversed most DEN-induced gene expression changes, particularly in cancer-related pathways.
  • Specificity protein 1 (SP1) was identified as a key regulator of DR's protective effects.

Conclusions:

  • Dietary restriction (DR) demonstrates significant protective effects against diethylnitrosamine-induced hepatocellular carcinoma (HCC) in mice.
  • DR functions by restoring disturbed gene expression profiles, highlighting its therapeutic potential.
  • The findings identify SP1 as a crucial regulator and suggest potential molecular targets for HCC therapy.